drugset / Trial / NCT00480896

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

NCT00480896

Phase 3 Completed 250 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.

Timeline

Start
2004-06
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.03 % Topical

Indications